Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Early anti-latency reversing therapy and broadly neutralizing antibodies during ART initiation to limit HIV-1 reservoir
2015-002234-53Phase 2Completed
- Sponsor
- Aarhus University Hospital
- Start
- Jul 2016
- Modality
- Small Molecules, Anti-infectious Disease mAbs → Neutralizing Antibodies → Monoclonal Antibodies → Antibody-Based Therapeutics, Naked Antibodies → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised trial of romidepsin and Teropavimab in human immunodeficiency virus infection (HIV) (4 arms), sponsored by Aarhus University Hospital. Primary endpoint: Change in HIV-1 reservoir size. Started Jul 2016; status: completed.
02
Drugs
romidepsinTeropavimab
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on 2015-002234-53.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-002234-53.